Nyxoah SA
Key Metrics
- Previous Close
- $0.88
- 52-Week Range
- $0.80 – $5.39
- Market Cap
- $87.89M
- P/E (TTM)
- —
- EPS (TTM)
- -1.83
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 1.15
- PEG Ratio
- —
- Return on Equity
- -151.79%
- Return on Assets
- -42.06%
- Gross Margin
- 61.09%
- Operating Margin
- -282.53%
- Profit Margin
- 0.00%
- Current Ratio
- 2.19
- Debt/Equity
- 0.79
- Total Debt
- $53.86M
- Free Cash Flow
- $-46.00M
- Revenue Growth
- 365.00%
- Earnings Growth
- —
- Enterprise Value
- $64.67M
Market Snapshot
About
Nyxoah is a Belgium-based medical technology company developing innovative neurostimulation therapy for obstructive sleep apnea. The company's lead product is a bilateral hypoglossal nerve stimulation system that treats moderate to severe sleep apnea.